Literature DB >> 16962649

Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?

Christine E Marx1, Lawrence J Shampine, Gary E Duncan, Margaret J VanDoren, A Chistina Grobin, Mark W Massing, Roger D Madison, Daniel W Bradford, Marian I Butterfield, Jeffrey A Lieberman, A Leslie Morrow.   

Abstract

Clozapine demonstrates superior efficacy in patients with schizophrenia, but the precise mechanisms contributing to this clinical advantage are not clear. Clozapine and olanzapine increase the GABAergic neuroactive steroid (NS) allopregnanolone, and it has been hypothesized that NS induction may contribute to the therapeutic actions of these agents. Pregnenolone administration improves learning and memory in rodent models, and decreases in this NS have been associated with depressive symptoms in humans. These pregnenolone characteristics may be relevant to the actions of antipsychotics. We therefore investigated potential pregnenolone alterations in rat hippocampus and cerebral cortex following clozapine, olanzapine, and other second generation agents as a candidate NS mechanism contributing to antipsychotic efficacy. In the first set of experiments, intact, adrenalectomized, and sham-operated male rats received vehicle or clozapine (20 mg/kg) IP. In the second set, male rats received vehicle, olanzapine (5 mg/kg), quetiapine (20 mg/kg), ziprasidone (10 mg/kg) or aripiprazole (5 mg/kg) IP. Pregnenolone levels were determined by gas chromatography/mass spectrometry. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum; hippocampal levels were strongly correlated with serum levels (r=0.987). Olanzapine also elevates pregnenolone levels, but to a lesser degree than clozapine. Pregnenolone induction may contribute to the clinical actions of clozapine and olanzapine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962649     DOI: 10.1016/j.pbb.2006.07.026

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  28 in total

1.  Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.

Authors:  Olakunle James Onaolapo; Olayemi Quyyom Ademakinwa; Temitayo Opeyemi Olalekan; Adejoke Yetunde Onaolapo
Journal:  Psychopharmacology (Berl)       Date:  2017-06-14       Impact factor: 4.530

2.  Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage.

Authors:  Jennifer C Naylor; Christine M Hulette; David C Steffens; Lawrence J Shampine; John F Ervin; Victoria M Payne; Mark W Massing; Jason D Kilts; Jennifer L Strauss; Patrick S Calhoun; Rohana P Calnaido; Daniel G Blazer; Jeffrey A Lieberman; Roger D Madison; Christine E Marx
Journal:  J Clin Endocrinol Metab       Date:  2008-05-13       Impact factor: 5.958

Review 3.  GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.

Authors:  S Hossein Fatemi; Timothy D Folsom
Journal:  Schizophr Res       Date:  2014-11-26       Impact factor: 4.939

4.  Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Authors:  Jennifer C Naylor; Jason D Kilts; Christine M Hulette; David C Steffens; Dan G Blazer; John F Ervin; Jennifer L Strauss; Trina B Allen; Mark W Massing; Victoria M Payne; Nagy A Youssef; Lawrence J Shampine; Christine E Marx
Journal:  Biochim Biophys Acta       Date:  2010-05-19

5.  Existing and novel biological therapeutics in suicide prevention.

Authors:  Joshua J Griffiths; Carlos A Zarate; J J Rasimas
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

6.  Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia.

Authors:  HuaLin Cai; Xiang Zhou; George G Dougherty; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Matcheri Keshavan; Jeffrey K Yao
Journal:  Psychoneuroendocrinology       Date:  2018-02-07       Impact factor: 4.905

7.  Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Christine E Marx; Lawrence J Shampine; Susan S Girdler; A Leslie Morrow
Journal:  Steroids       Date:  2009-01-13       Impact factor: 2.668

8.  Evidence for a role of progesterone in menstrual cycle-related variability in prepulse inhibition in healthy young women.

Authors:  Veena Kumari; Joanna Konstantinou; Andrew Papadopoulos; Ingrid Aasen; Lucia Poon; Rozmin Halari; Anthony J Cleare
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

Review 9.  A review of anti-inflammatory agents for symptoms of schizophrenia.

Authors:  William R Keller; Lionel M Kum; Heidi J Wehring; Maju Mathew Koola; Robert W Buchanan; Deanna L Kelly
Journal:  J Psychopharmacol       Date:  2012-11-13       Impact factor: 4.153

10.  Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits.

Authors:  Rebecca K Sripada; Christine E Marx; Anthony P King; Jessica C Rampton; S Shaun Ho; Israel Liberzon
Journal:  Biol Psychiatry       Date:  2013-01-21       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.